Of note, a patient with RAS wild-type FGFR2 fused pancreatic cancer attained a deep and durable response, and it is now established that such alterations are seen in <1% patients with pancreatic ductal adenocarcinoma, indicating the need to identify these patients with clinical grade genotyping. Here, FGFR2 is linked to pancreatic neoplasm.